Evolving NCCN Guidelines for MPNs

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

Zanidatamab combined with chemotherapy demonstrated promising antitumor activity and safety in the first-line treatment of HER2-positive mCRC, with a high response rate and manageable adverse effects.

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

Adding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Neoadjuvant endocrine therapy followed by targeted therapy led to excellent survival outcomes in patients with hormone-receptor-positive, HER2-positive early breast cancer.